Claritev (NYSE:CTEV) SVP Tiffani Misencik Sells 8,850 Shares

Claritev (NYSE:CTEV) SVP Tiffani Misencik sold 8,850 shares of the stock in a transaction on Friday, August 14th. The shares were sold at an average price of $40.07, for a total transaction of $354,619.50. Following the transaction, the senior vice president owned 123,723 shares in the company, valued at $4,957,580.61. This trade represents a 6.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Claritev Trading Up 0.2%

CTEV stock traded up $0.07 during mid-day trading on Tuesday, hitting $35.42. 107,223 shares of the company were exchanged, compared to its average volume of 164,811. The firm has a fifty day simple moving average of $30.01 and a 200 day simple moving average of $24.08. The company has a market capitalization of $600.26 million, a PE ratio of -2.08 and a beta of 0.74. Claritev has a twelve month low of $11.50 and a twelve month high of $74.07.

Claritev (NYSE:CTEV) last issued its earnings results on Friday, August 7th. The company reported $1.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.10) by $5.51. The company had revenue of $257.48 million during the quarter. As a group, sell-side analysts anticipate that Claritev will post -15.08 earnings per share for the current year.

Hedge Funds Weigh In On Claritev

Several institutional investors have recently made changes to their positions in CTEV. Arini Captial Management Ltd acquired a new position in Claritev during the 4th quarter valued at approximately $64,291,000. Beach Point Capital Management LP increased its position in Claritev by 77.4% in the fourth quarter. Beach Point Capital Management LP now owns 755,002 shares of the company’s stock worth $32,276,000 after buying an additional 329,424 shares during the period. Verition Fund Management LLC bought a new stake in Claritev in the third quarter valued at $767,000. XTX Topco Ltd bought a new stake in Claritev in the fourth quarter valued at $729,000. Finally, Jump Financial LLC acquired a new position in shares of Claritev during the fourth quarter valued at $397,000. 87.15% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Canaccord Genuity Group lifted their target price on Claritev from $37.00 to $43.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Citigroup reissued a “buy” rating and set a $45.00 price target (up from $40.00) on shares of Claritev in a research report on Monday, August 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Claritev in a report on Wednesday, June 24th. Wall Street Zen upgraded shares of Claritev from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Barclays initiated coverage on shares of Claritev in a report on Friday, April 24th. They set an “overweight” rating and a $28.00 target price on the stock. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Claritev has an average rating of “Moderate Buy” and an average price target of $42.83.

About Claritev

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.